Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cediranib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Cediranib. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-000383-24 Sponsor Protocol Number: D8480C00055 Start Date*: 2008-02-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib...
    Medical condition: Glioblastoma - a primary brain tumour
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) CZ (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021531-13 Sponsor Protocol Number: UCL/10/0035 Start Date*: 2011-02-17
    Sponsor Name:Joint UCLH and UCL Biomedical Research Unit
    Full Title: Multi-centre, randomised, double-blind phase II study comparing cediranib (AZD2171) plus gefitinib (Iressa, ZD1839) with cediranib plus placebo in subjects with recurrent/progressive glioblastoma (...
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018275-20 Sponsor Protocol Number: UMCNONCO201001 Start Date*: 2010-03-24
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
    Medical condition: symptomatic malignant ascites or pleural effusion
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025538 Malignant ascites LLT
    12.1 10026673 Malignant pleural effusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001045-40 Sponsor Protocol Number: GEM-1805 Start Date*: 2020-03-03
    Sponsor Name:Grupo Español Multidisciplinar de Melanoma
    Full Title: Phase II, Open-Label Study of preliminary efficacy of Durvalumab (MEDI4736) in Combination with Cediranib in Patients with Metastatic Uveal Melanoma
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081431 Uveal melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018014-20 Sponsor Protocol Number: COSAKV1 Start Date*: 2010-04-19
    Sponsor Name:Common Services Agency
    Full Title: A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer
    Medical condition: Clear Cell Renal Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004618-93 Sponsor Protocol Number: R120502 Start Date*: 2017-12-12
    Sponsor Name:University of Manchester
    Full Title: Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer
    Medical condition: Platinum-Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003056-21 Sponsor Protocol Number: WIRE Start Date*: 2020-02-07
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.
    Medical condition: Surgically resectable renal cell cancer (Stage M0/M1)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000559-28 Sponsor Protocol Number: OCTO-062 Start Date*: 2017-01-25
    Sponsor Name:University of Oxford
    Full Title: Randomised phase II Trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum–resistant ovarian cancer
    Medical condition: BRCA mutated platinum-resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001155-39 Sponsor Protocol Number: D8480C00016 Start Date*: 2012-03-09
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I trial of AZD2171, an orally bioavailable antiangiogenic agent, in children and adolescents with refactory or recurrent solid tumours or acute myelogenous leukemia
    Medical condition: Refractory or recurrent solid tumours or acute myelogenous leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001192-23 Sponsor Protocol Number: OZM-060 Start Date*: 2017-09-18
    Sponsor Name:University Health Network, Toronto
    Full Title: A proof of concept, multi-centre, clinical trial of the combination cediranib-olaparib at the time of disease progression on PARP inhibitor in ovarian cancer.
    Medical condition: Clinical trial of the combination cediranib-olaparib at the time of disease progression on PARP inhibitor in ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-003964-38 Sponsor Protocol Number: IRFMN-OVA-7289 Start Date*: 2017-03-21
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: The BAROCCO study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian multicenter randomized phase II study of weekly paclitaxel vs. Cediranib-Olaparib with continuous ...
    Medical condition: resistant high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070907 Ovarian cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070908 Ovarian cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011542-25 Sponsor Protocol Number: C-2009-01 Start Date*: 2010-01-07
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: CIRCCa(Cediranib In Recurrent Cervical Cancer) A Randomised Double Blind Phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent c...
    Medical condition: Metastatic/ Recurrent carinoma of cervix
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041848 Squamous cell carcinoma of the cervix PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008224 Cervical adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001154-26 Sponsor Protocol Number: PBTC-020 Start Date*: 2012-03-09
    Sponsor Name:Pediatric Brain Tumour Consortium
    Full Title: A phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumours
    Medical condition: Recurrent, Progressive, or Refactory Primary CNS Tumours
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2010-021163-33 Sponsor Protocol Number: CCR3448 Start Date*: 2011-03-08
    Sponsor Name:The Institute of Cancer Research [...]
    1. The Institute of Cancer Research
    2. The Royal Marsden Hospital NHS Foundation Trust
    Full Title: A Phase II Trial of Cediranib in the Treatment of Patients with Alveolar Soft Part Sarcoma (CASPS).
    Medical condition: Alveolar Soft Part Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001883 Alveolar soft part sarcomas HLT
    20.0 100000004864 10001883 Alveolar soft part sarcomas HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006250-25 Sponsor Protocol Number: D8480C00034 Start Date*: 2008-02-29
    Sponsor Name:ASTRAZENECA
    Full Title: A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN™) (30 mg) When Added to Gemcitabine and Cisplatin versus the Effica...
    Medical condition: Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025052 Lung cancer non-small cell stage III LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004617-28 Sponsor Protocol Number: Start Date*: 2017-11-30
    Sponsor Name:The University of Manchester
    Full Title: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometria...
    Medical condition: Advanced or recurrent endometrial carcinoma or carcinosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013408-30 Sponsor Protocol Number: 2009-013408-30 Start Date*: 2010-08-23
    Sponsor Name:University College London
    Full Title: Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers
    Medical condition: biliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10004595 Bile duct cancer NOS LLT
    17.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    17.0 100000004864 10017617 Gallbladder cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000161-75 Sponsor Protocol Number: UCL/14/0795 Start Date*: 2017-12-18
    Sponsor Name:University College London
    Full Title: An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer...
    Medical condition: High grade serous or endometrioid ovarian, fallopian and peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-003883-36 Sponsor Protocol Number: CFTSp104 Start Date*: 2017-02-01
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: Single arm feasibility of multi-maintenance olaparib after disease recurrence in participants with platinum sensitive BRCAm high grade serous ovarian cancer
    Medical condition: platinum sensitive BRCAm high grade serous ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-004215-13 Sponsor Protocol Number: CCC844 Start Date*: 2017-12-29
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation
    Full Title: Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer (COMICE)
    Medical condition: Advanced recurrent and metastatic cervical cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008231 Cervical cancer recurrent LLT
    20.0 100000004864 10008235 Cervical cancer stage III LLT
    20.0 100000004864 10008236 Cervical cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA